NextCure (NASDAQ:NXTC – Get Free Report) will likely be announcing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect NextCure to announce earnings of ($0.90) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:00 PM ET.
NextCure (NASDAQ:NXTC – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.95) by ($0.85).
NextCure Stock Down 1.9%
NXTC opened at $5.61 on Wednesday. NextCure has a 52-week low of $1.55 and a 52-week high of $15.74. The firm’s fifty day simple moving average is $6.11 and its two-hundred day simple moving average is $7.99.
Insider Buying and Selling
In other NextCure news, major shareholder Adar1 Capital Management, Llc acquired 5,626 shares of the company’s stock in a transaction on Friday, October 23rd. The shares were bought at an average cost of $4.83 per share, for a total transaction of $27,173.58. Following the completion of the purchase, the insider owned 728,045 shares in the company, valued at $3,516,457.35. This trade represents a 0.78% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have acquired 340,004 shares of company stock valued at $1,676,791. 11.90% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
A number of analysts have recently issued reports on NXTC shares. Weiss Ratings lowered NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. HC Wainwright reiterated a “buy” rating on shares of NextCure in a research report on Thursday, August 13th. Finally, Wall Street Zen upgraded shares of NextCure from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $19.00.
Read Our Latest Research Report on NXTC
About NextCure
NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.
NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.
Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.
Featured Articles
- Five stocks we like better than NextCure
- Is United Parcel Service Finally Turning the Corner?
- Taiwan Semiconductor Flexes Pricing Power on AI’s Frontline
- Hidden in Plain Sight: 2 Earnings Winners Investors May Have Missed
- These 3 New ETFs Are Turning Heads—Are They Worth Buying?
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.
